Trial Profile
An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc; Plexxikon
- 24 Jun 2020 Results of a genomic analysis using (FFPE) TGCT specimens from six clinical studies: NCT01004861, NCT02777710, NCT01217229, NCT01525602, NCT01790503 and NCT02452424 assessing CSF1 genetic alterations and rearrangements presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 19 Jun 2020 Status changed from active, no longer recruiting to completed.
- 18 Feb 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.